SCHEMBL5419664

SCHEMBL5419664

Cc1ccc(C(=O)NS(=O)(=O)C=Cc2ccccc2Cl)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 1/20 0.43
NFE2L2 Q16236 5/20 0.42
FLT1 P17948 5/20 0.40
FLT4 P35916 5/20 0.40
KDR P35968 5/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5419660 1.00 PTGES2 (0.43) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL4620146 0.88 FLT1 (0.53) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL5412813 0.88 FLT1 (0.51) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL5412829 0.88 FLT1 (0.51) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL4620137 0.88 FLT1 (0.53) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL5403998 0.86 PTGES2 (0.43) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL5404009 0.86 PTGES2 (0.43) PTGES2NFE2L2FLT1FLT4KDR
SCHEMBL5414746 0.84 PTGES2 (0.47) PTGES2NFE2L2MAPTMEN1KMT2A
SCHEMBL5414752 0.84 PTGES2 (0.47) PTGES2NFE2L2MAPTMEN1KMT2A
SCHEMBL4620421 0.84 FLT1 (0.53) PTGES2NFE2L2FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 PTGES2 3551/4885NFE2L2 1842/4885FLT1 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.